Elix Provides AI Drug Discovery Platform to KYORIN Pharmaceutical
Elix, Inc. has announced that KYORIN Pharmaceutical Co., Ltd. has adopted its AI-powered drug discovery platform, Elix Discovery™. This platform is designed to streamline the drug discovery process by utilizing AI technologies for molecular design and compound profiling.
Elix Discovery™ features an intuitive graphical user interface that allows users to build predictive models for optimal compound profiling. It supports both ligand-based and structure-based drug design, incorporating tools like docking simulations to enhance the drug discovery process.
The collaboration aims to accelerate KYORIN's research and improve its quality by integrating AI-driven drug discovery with KYORIN's existing capabilities. This partnership reflects a growing trend in the pharmaceutical industry to leverage AI technologies to address challenges such as long development timelines and high R&D costs.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 2 NAMI joins Common Sense Media youth AI safety standards program Nov 1 Midstream Health Raises $20M to Recover Hospital Payments Oct 31 AI Agent Controls Brain Injection in Live Mouse After Claude Opus Refuses Oct 31 Patient Sues Allegheny Health Network and Highmark Over Abridge AI Recordings Oct 31 OpenAI Releases GPT-Rosalind-6 for Approved Biology ResearchersLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Tensordyne Napier: What If One Rack Could Do the Work of Nine?
Tensordyne
This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.
Read moreYou may also like
ALLOX Raises $10.5 Million for AI Drug Discovery Platform
Apodex Offers Free AI Drug Research Services
Flagship Pioneering Merges Three Biotech Platforms Into Etcelera
Phylo Brings Biomni Lab AI Agents to Bayer
Illumina Adds Three Research Tools to BioInsight Platform
Daily AI Brief: the AI news that matters, in your inbox.